Attached files

file filename
10-Q - QUARTERLY REPORT - DYNASIL CORP OF AMERICAv230358_10q.htm
EX-32.1 - EXHIBIT 32.1 - DYNASIL CORP OF AMERICAv230358_ex32-1.htm
EX-31.1(A) - EXHIBIT 31.1(A) - DYNASIL CORP OF AMERICAv230358_ex31-1a.htm
EX-31.1(B) - EXHIBIT 31.1(B) - DYNASIL CORP OF AMERICAv230358_ex31-1b.htm
EXCEL - IDEA: XBRL DOCUMENT - DYNASIL CORP OF AMERICAFinancial_Report.xls

Contacts:
 
Patty Kehe
Dynasil Corporation of America
Phone: (607) 272-3320, ext. 26
Email: pkehe@dynasilcorp.com

David Calusdian
Executive Vice President and Partner
Sharon Merrill
617.542.5300
DYSL@InvestorRelations.com

 
Dynasil Corporation Reports 8% Revenue Growth
in Third Quarter of Fiscal 2011
 
Company Plans Dual-Mode Radiation Detector Revenue in FY 2012
 
Announces Planning Initiative to Focus Commercialization Efforts
 

Watertown, Mass., August 15, 2011 – Dynasil Corporation of America (NASDAQ: DYSL) today announced financial results for the fiscal 2011 third quarter ended June 30, 2011.

Revenue for the third quarter of fiscal 2011 was $12.2 million, an increase of 8% from revenue of $11.3 million for the third quarter of fiscal 2010.  Net income was $1 million, or 7 cents per diluted share, up from $0.7 million, or 5 cents per diluted share, in the third quarter of 2010.

Revenue for the nine months ended June 30, 2011 was $35.9 million, an increase of 14.0% from revenue of $31.5 million for the same period in 2010.  Net Income for the nine months ended June 30, 2011 was $1,798,073, or $0.12 in basic earnings per share, compared to $1,974,713, or $0.13 in basic earnings per share, for the comparable period ended June 30, 2010.

“We reported another quarter of strong year-over-year revenue growth, fueled by increases in both our Contract Research and Products & Instruments segments,” said Dynasil President Steven Ruggieri.   “Due to the significant investments we are making to build shareholder value for the long-term, selling, general and administrative expenses increased by 44% in the quarter. In addition, during the quarter, Dynasil was successful in qualifying for U.S. Research & Experimentation Tax Credits totaling approximately $1.0 million.  Overall results for the quarter showed a 41% increase in net income.”

Income from operations in the 2011 period includes $583,000 in costs related to the initial operation of Dynasil Biomedical Corp., the startup of the dual mode detector initiative, a study to determine Dynasil’s qualification for U.S. Research & Experimentation Tax Credits and transition of the Company’s executive management.  In addition to the costs mentioned above, net income includes approximately $1,045,000 in U.S. Research & Experimentation Tax Credits for the years 2009 and 2010.
 
 
 

 
 
“During the quarter we made excellent progress toward the commercialization of our dual mode radiation detectors,” added Ruggieri. “Delivery is underway of our dual mode detectors to OEM customers for beta testing, and we expect to begin to produce revenue from this program in fiscal year 2012, marking a key milestone for Dynasil.  We see a broad set of addressable market opportunities for our dual-mode products.  Applications include detection of nuclear bombs and materials at ports and border checkpoints, and radiation detection at nuclear energy facilities.”

“The dual-mode radiation detectors are one example of how Dynasil has taken great strides in transitioning from a largely research-based organization to a more commercial enterprise,” said Ruggieri.  “Commercialization of technology from our extensive research and development portfolio and acquisitions are expected to be the key drivers of our future growth, and we plan to continue to invest in these growth opportunities.  The Company is actively exploring commercialization opportunities in thin film digital x-rays, sensors for non destructive testing and radiation dosimeters based on technologies developed at our RMD (Radiation Monitoring Devices, Inc.) subsidiary.  While still early, many of the technologies being explored within our biomedical opportunity also have exciting market potential.”

“Our mission is to accelerate this commercial transition by identifying and dedicating the necessary resources to those opportunities that have the greatest potential for profitable growth,” Ruggieri continued.  “To do so, we are working on a long-range business plan that includes a focus on rationalizing our research and commercialization efforts.  This plan, which we will roll out in fiscal year 2012,  will streamline our businesses to position Dynasil for continued profitability and increased  shareholder value for the long-term.”

Conference Call Information
Dynasil Corporation will host a conference call for investors and analysts tomorrow, Tuesday, August 16, 2011 at 5:00 p.m. ET.  On the call will be Dynasil President Steven Ruggieri, Chief Financial Officer Richard Johnson and Chairman Peter Sulick. Those who wish to listen to the conference call and view presentation slides should visit the Investor Information section of the Company’s website at www.dynasilcorp.com. The call also may be accessed by dialing (877) 407-5790 or (201) 689-8328.  For interested individuals unable to join the live conference call, a webcast replay will be available on the Company’s website for one year.

About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, industrial and biomedical markets.  Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing.  Through its Dynasil Biomedical unit, the Company is developing early stage opportunities for the biomedical technology area.  Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at www.dynasilcorp.com.
 
 
 

 
 
Safe Harbor
This news release may contain forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act.  These statements about our expectations, beliefs, plans, designs, objectives, prospects, financial condition, assumptions or future events or performance, including, but not limited to: the Company’s plans to deliver its dual mode detectors to OEM customers for beta testing with early adopters and begin to produce revenue in fiscal year 2012; the expectation that commercialization of technology from the Company’s extensive research and development portfolio and acquisitions are expected to be the key drivers of future growth; Dynasil’s plan to continue to invest in these growth opportunities; the Company’s expectation that it will introduce a long-range business plan in fiscal year 2012 that will position Dynasil for continued profitability and build shareholder value for the long-term; the future markets and demand for our products; new research and development initiatives; commercialization opportunities for Dynasil Biomedical; and potential acquisition activities are forward-looking statements that involve a number of risks and uncertainties.  Future results of operations, projections, and expectations, which may relate to this release, involve certain risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the factors detailed in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as in the Company's other Securities and Exchange Commission filings.

 
 
 

 
 
Dynasil Corporation of America and Subsidiaries
           
Consolidated Balance Sheets
           
 
 
30-Jun
   
30-Sep
 
   
2011
   
2010
 
ASSETS
 
(Unaudited)
       
Current assets
           
   Cash and cash equivalents
  $ 4,644,397     $ 4,111,966  
   Accounts receivable, net
    5,812,716       6,360,583  
   Inventories
    3,074,760       3,097,219  
Cost in excess of billings
    -0-       135,157  
Deferred tax asset
    485,903       598,335  
Prepaid income taxes
    118,155       166,231  
Prepaid expenses and other current assets
    568,832       453,418  
                     Total current assets
    14,704,763       14,922,909  
                 
Property, Plant and Equipment, net
    4,708,973       3,953,319  
Other Assets
               
   Intangibles, net
    6,223,534       6,671,149  
   Goodwill
    13,446,382       13,591,287  
   Deferred tax asset
    613,136       -0-  
   Deferred financing costs, net
    160,634       190,568  
                     Total other assets
    20,443,686       20,453,004  
                 
                     Total Assets
  $ 39,857,422     $ 39,329,232  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
Current Liabilities
               
   Current portion of long-term debt
  $ 1,868,531     $ 1,870,779  
   Accounts payable
    1,478,694       1,482,250  
   Accrued expenses and other liabilities
    1,978,219       2,177,743  
   Contingent consideration
    279,600       -0-  
   Deferred tax liability
    163,322       91,100  
   Dividends payable
    -0-       131,400  
                     Total current liabilities
    5,768,366       5,753,272  
                 
Long-term Liabilities
               
   Long-term debt, net
    9,440,477       10,833,334  
   Contingent consideration
    -0-       750,000  
                    Total long-term liabilities
    9,440,477       11,583,334  
                 
Temporary Equity
    2,000,000       2,000,000  
                 
Stockholders' Equity
    22,648,579       19,992,626  
                 
Total Liabilities and Stockholders' Equity
  $ 39,857,422     $ 39,329,232  
 
 
 

 
 
DYNASIL CORPORATION OF AMERICA AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
 
   
Three Months Ended
   
Nine Months Ended
 
   
June 30,
   
June 30,
 
   
2011
   
2010
   
2011
   
2010
 
Net revenue
  $ 12,153,175     $ 11,294,868     $ 35,896,030     $ 31,494,960  
Cost of revenue
    7,012,611       6,562,323       21,136,257       18,669,123  
Gross profit
    5,140,564       4,732,545       14,759,773       12,825,837  
Selling, general and administrative expenses
    4,911,288       3,399,584       12,978,126       9,311,918  
Income from operations
    229,276       1,332,961       1,781,647       3,513,919  
Interest expense, net
    148,563       142,578       461,916       457,007  
Income before income taxes (benefit)
    80,713       1,190,383       1,319,731       3,056,912  
Income taxes (benefit)
    (946,165 )     462,737       (478,342 )     1,082,199  
Net income
  $ 1,026,878     $ 727,646     $ 1,798,073     $ 1,974,713  
                                 
                                 
Net Income
  $ 1,026,878     $ 727,646     $ 1,798,073     $ 1,974,713  
Foreign currency translation, net of $72,222
                               
 and $ -0- income taxes in 2011 and 2010
    47,118       -0-       185,712       -0-  
Total comprehensive income
  $ 1,073,996     $ 727,646     $ 1,983,785     $ 1,974,713  
 
                               
                                 
Net income
  $ 1,026,878     $ 727,646     $ 1,798,073     $ 1,974,713  
Dividends on preferred stock
    -0-       131,400       116,646       406,033  
Net income applicable to common stockholders
    1,026,878       596,246       1,681,427       1,568,680  
Dividend add back due to preferred stock conversion
    -0-       131,400       116,646       406,033  
Net income for diluted income per common share
  $ 1,026,878     $ 727,646     $ 1,798,073     $ 1,974,713  
                                 
Basic net income per common share
  $ 0.07     $ 0.05     $ 0.12     $ 0.13  
Diluted net income per common share
  $ 0.07     $ 0.05     $ 0.12     $ 0.13  
                                 
Weighted average shares outstanding
                               
Basic
    15,394,811       12,610,116       14,448,875       12,315,532  
Diluted
    15,748,591       14,982,382       14,802,655       14,687,798